Arizona State Retirement System raised its position in Krystal Biotech, Inc. (NASDAQ:KRYS – Get Rating) by 21.3% during the 1st quarter, according to its most recent filing with the SEC. The institutional investor owned 4,712 shares of the company’s stock after acquiring an additional 827 shares during the period. Arizona State Retirement System’s holdings in Krystal Biotech were worth $314,000 as of its most recent filing with the SEC.
Other institutional investors have also recently bought and sold shares of the company. Confluence Wealth Services Inc. bought a new stake in shares of Krystal Biotech during the 4th quarter worth approximately $25,000. Lazard Asset Management LLC raised its stake in shares of Krystal Biotech by 21.0% during the 4th quarter. Lazard Asset Management LLC now owns 1,272 shares of the company’s stock worth $88,000 after purchasing an additional 221 shares in the last quarter. Dupont Capital Management Corp bought a new stake in shares of Krystal Biotech during the 4th quarter worth approximately $177,000. Victory Capital Management Inc. bought a new stake in shares of Krystal Biotech during the 4th quarter worth approximately $200,000. Finally, Allspring Global Investments Holdings LLC bought a new stake in shares of Krystal Biotech during the 4th quarter worth approximately $229,000. Institutional investors own 76.57% of the company’s stock.
Krystal Biotech Trading Up 6.5 %
KRYS opened at $78.54 on Friday. Krystal Biotech, Inc. has a 1-year low of $38.86 and a 1-year high of $102.99. The stock’s fifty day simple moving average is $66.22 and its 200 day simple moving average is $63.88. The stock has a market cap of $2.01 billion, a PE ratio of -17.97 and a beta of 0.88.
Wall Street Analyst Weigh In
Separately, The Goldman Sachs Group dropped their price objective on Krystal Biotech from $91.00 to $78.00 and set a “buy” rating on the stock in a research note on Tuesday, May 24th.
About Krystal Biotech
Krystal Biotech, Inc, a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa.
- Get a free copy of the StockNews.com research report on Krystal Biotech (KRYS)
- How Does Freeport McMoran Inc Compare to Its Sector Competitors?
- 3 Hotel Stocks to Consider Checking into After Earnings
- Can FuelCell Energy Surge Higher This Year?
- Is It Time to Take a Ride on Cedar Fair Stock?
- These Are The Top Insider Buying Stocks For July
Want More Great Investing Ideas?
- Bear Market Game Plan!
- The 10 Best Stocks to Own in 2022
- 7 Stocks to Buy and Hold Forever
- 3 Stocks to DOUBLE This Year
Receive News & Ratings for Krystal Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Krystal Biotech and related companies with MarketBeat.com's FREE daily email newsletter.